US45337C1027
© BusinessWire
12.12.2025
INCY
LISTED
NASDAQ
Incyte Announces Change to its Board of Directors
News Preview
Incyte (Nasdaq:INCY) today announced the resignation of Hervé Hoppenot from the Company’s Board of Directors, effective immediately. As previously announced, Mr. Hoppenot had been serving as an advisor to the Chief Executive Officer (CEO) and as a member of the Board during a planned transition period.
Mr. Hoppenot joined Incyte in 2014 and previ...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
INCY
LISTED
NASDAQ
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
News Preview
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, as a treatment for patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). These data, which are featured in o...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2025
INCY
LISTED
NASDAQ
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
News Preview
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, for the treatment of patients with essential thrombocythemia (ET) harboring a Type 1 CALR mutation who are resistant or intole...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
07.12.2025
INCY
LISTED
NASDAQ
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
News Preview
Incyte (Nasdaq:INCY) today announced new clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, for patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). These preliminary results are from the dose escalation...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
03.12.2025
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Incyte Corporation (Nasdaq: INCY) announced today equity inducement awards grants to Richard Hoffman, Company’s new Executive Vice President and General Counsel, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
INCY
LISTED
NASDAQ
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
News Preview
Incyte (Nasdaq:INCY) today announced its partnership with world renowned supermodel and beauty entrepreneur Winnie Harlow — one of the most recognizable people living with vitiligo — to raise awareness of vitiligo through “The Power of Choice” campaign.
This press release features multimedia. View the full release here: https://www.businesswire.co...
Themefolio
Profiler
Peergroup
© BusinessWire
01.12.2025
INCY
LISTED
NASDAQ
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
News Preview
Incyte (Nasdaq:INCY) announces the appointment of Richard Hoffman as Executive Vice President and General Counsel effective today, December 1, 2025. In his new role, Mr. Hoffman will serve as a key member of the Executive Leadership Team and be responsible for the Company’s legal and compliance teams.
“Richard joins us with a distinguished backgr...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2025
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conferences
News Preview
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of December:
Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 11:15 am (EST)
8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 1:20 pm (EST)
The presentations will be webcast li...
Themefolio
Profiler
Peergroup
© BusinessWire
17.11.2025
INCY
LISTED
NASDAQ
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)
News Preview
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lympho...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
INCY
LISTED
NASDAQ
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
News Preview
Incyte (Nasdaq:INCY) today announced the expansion of its Moments of Clarity program, which amplifies the voices of people living with chronic immune-mediated skin conditions. This year, the initiative introduces six compelling new stories that spotlight the true lived experiences of people living with nonsegmental vitiligo and mild-to-moderate at...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
INCY
LISTED
NASDAQ
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
News Preview
Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual Meeting, to be held December 6 – 9, 2025, in Orlando.
"This year’s Incyte presentations highlight the potential of our portfolio to transform the tre...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conferences
News Preview
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November:
Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am (EST)
Jefferies Global Healthcare Conference (London) on Tuesday, November 18, 2025 at 11:00 am (GMT)
The presentations w...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
28.10.2025
INCY
LISTED
NASDAQ
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
News Preview
Incyte (Nasdaq:INCY) today reported financial results for the third quarter of 2025 and provided a business update.
“Our third-quarter results demonstrate strong growth across our product portfolio, with net product revenues increasing 19% year-over-year, which highlights the momentum in our business and effective commercial execution,” said Bil...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
INCY
LISTED
NASDAQ
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
News Preview
Incyte (NASDAQ:INCY) and Enable Injections, Inc. (“Enable”) today announced a new partnership to develop and commercialize specific assets in Incyte’s portfolio, including its investigational, first-in-class mutant calreticulin (mutCALR) selective monoclonal antibody, with Enable’s enFuse® On-Body Delivery System.
This press release features mult...
Themefolio
Profiler
Peergroup
© BusinessWire
26.10.2025
INCY
LISTED
NASDAQ
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
News Preview
Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data wil...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
INCY
LISTED
NASDAQ
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
News Preview
This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials
New data show 71% of adolescents with severe disease treated with baricitini...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
INCY
LISTED
NASDAQ
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
News Preview
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (P...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
INCY
LISTED
NASDAQ
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
News Preview
Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology (ESMO) Congress 20...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2025
INCY
LISTED
NASDAQ
Incyte to Report Third Quarter Financial Results
News Preview
Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 28, 2025.
The schedule for the press release and conference call/webcast is as follows:
Q3 2025 Press Release: October 28, 2025 at 7:00 a.m. ET
Q3 2025 Conference Call: October 28,...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Incyte (Nasdaq:INCY) announced today equity inducement awards grants to David H. Gardner, the Company’s new Executive Vice President, Chief Strategy Officer, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the new...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
INCY
LISTED
NASDAQ
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
News Preview
Incyte (Nasdaq:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer (CSO) effective today, September 22, 2025. In his new role, Mr. Gardner will serve as a key member of the Executive Leadership Team and be responsible for the Company’s strategy and business development.
"Dave possesses a uniqu...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
INCY
LISTED
NASDAQ
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
News Preview
Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura® (ruxolitinib) cream 1.5%, a topical Janus kinase (JAK) inhibitor, for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised children two years of age and older whose disease...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
INCY
LISTED
NASDAQ
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
News Preview
Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will support th...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
INCY
LISTED
NASDAQ
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
News Preview
Today Incyte (Nasdaq:INCY) announced that it will present new data from its dermatology portfolio at the European Association of Dermatology and Venerology (EADV) 2025 Congress, held from September 17 – 20, in Paris. Highlights include late-breaking, oral and poster presentations featuring data for povorcitinib (INCB054707), an oral small-molecule...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
INCY
LISTED
NASDAQ
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
News Preview
Incyte (Nasdaq:INCY) announced the launch of HS TRUTHS, a new educational campaign aimed at revealing the authentic and often hidden realities of living with hidradenitis suppurativa (HS), a chronic inflammatory skin condition. This initiative moves beyond superficial awareness by sharing the physical pain, emotional burden and years-long diagnost...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Incyte (Nasdaq: INCY) announced today equity inducement awards grants to Soni Basi, the Company’s new Executive Vice President and Chief Human Resources Officer, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
INCY
LISTED
NASDAQ
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
News Preview
Incyte (Nasdaq:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources Officer (CHRO) effective today, August 25, 2025. In her new role, Ms. Basi will serve as a key member of the Executive Leadership Team and be responsible for shaping the Company’s global human resources strategy including talent acqu...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2025
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conferences
News Preview
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:
Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at 8:00 am (EDT)
Well Fargo Healthcare Conference on Thursday, September 4, 2025 at 8:45 am (EDT)
Morgan Stanley 23rd Annual Global Healthcare Co...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
INCY
LISTED
NASDAQ
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
News Preview
Incyte (Nasdaq:INCY) today reports 2025 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.
"As I begin my tenure as CEO, I look forward to leading Incyte through its next phase of growth and value creation for patients, partners and shareholders. Our second quarter results reflect stro...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
INCY
LISTED
NASDAQ
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
News Preview
Incyte (Nasdaq:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, to be held October 17-21 in Berlin.
“We're looking forward to presenting the latest findings across our oncology portfolio at this year’s congress, including initial da...
Themefolio
Profiler
Peergroup
© BusinessWire
10.07.2025
INCY
LISTED
NASDAQ
Incyte to Report Second Quarter Financial Results
News Preview
Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025.
The schedule for the press release and conference call/webcast is as follows:
Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET
Q2 2025 Conference Call: July 29, 2025 at...
Themefolio
Profiler
Peergroup
© BusinessWire
02.07.2025
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Incyte Corporation (Nasdaq: INCY) announced today equity inducement awards grants to Bill Meury in connection with his appointment as the Company’s new President and Chief Executive Officer. The awards are made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and were approved by the compensation committee of the Company’s Board of D...
Themefolio
Profiler
Peergroup
© BusinessWire
26.06.2025
INCY
LISTED
NASDAQ
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
News Preview
Incyte (Nasdaq:INCY) today announced that the Company’s Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company’s Board of Directors, effective immediately.
Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will se...
Themefolio
Profiler
Peergroup
© BusinessWire
20.06.2025
INCY
LISTED
NASDAQ
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
News Preview
Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura®), a topical Janus kinase (JAK) inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis (AD). The Prescription...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
INCY
LISTED
NASDAQ
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
News Preview
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
This press re...
Themefolio
Profiler
Peergroup
© BusinessWire
15.06.2025
INCY
LISTED
NASDAQ
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
News Preview
Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in class, Incyte-discovered, targeted monoclonal antibody in patients with mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms (MPNs). These data – featured today in the Late...
Themefolio
Profiler
Peergroup
© BusinessWire
13.06.2025
INCY
LISTED
NASDAQ
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
News Preview
Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastati...
Themefolio
Profiler
Peergroup
© BusinessWire
06.06.2025
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 16,550 shares of the Company’s common stock to 19 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of June 2, 2025, and were approved by t...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
INCY
LISTED
NASDAQ
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
News Preview
Incyte (Nasdaq:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan.
"We're looking forward to presenting new data from across our hematology/oncology portfolio at the 2025 EHA Congress, including...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conference
News Preview
Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET).
The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.
About Incyte
A global biopharmaceutical company on a mission to Solve On., In...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
INCY
LISTED
NASDAQ
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
News Preview
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable loca...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,413 shares of the Company’s common stock and stock option awards to purchase an aggregate of 8,951 shares of the Company’s common stock to 60 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentiv...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conference
News Preview
Incyte (Nasdaq:INCY) announced today that it will present at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 1:40 pm (PDT).
The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.
About Incyte
A global biopharmaceutical company on a mission to Sol...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
INCY
LISTED
NASDAQ
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
News Preview
Incyte (Nasdaq:INCY) today reports 2025 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.
"The double-digit revenue growth in the first quarter driven by the continued growth of Jakafi and Opzelura and the recent launch of Niktimvo, puts us on track to achieve our full year objectives,"...
Themefolio
Profiler
Peergroup
© BusinessWire
25.04.2025
INCY
LISTED
NASDAQ
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
News Preview
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30.
“At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with mye...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
INCY
LISTED
NASDAQ
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
News Preview
Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago.
“The data featured at the 2025 ASCO Annual Meeting, from both our approved medicines and early-stage pipelin...
Themefolio
Profiler
Peergroup
© BusinessWire
10.04.2025
INCY
LISTED
NASDAQ
Incyte to Report First Quarter Financial Results
News Preview
Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 2025.
The schedule for the press release and conference call/webcast is as follows:
Q1 2025 Press Release: April 29, 2025 at 7:00 a.m. ET
Q1 2025 Conference Call: April 29, 2025 at...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 20,334 shares of the Company’s common stock to 24 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of April 1, 2025, and were approved by...
Themefolio
Profiler
Peergroup
© BusinessWire
17.03.2025
INCY
LISTED
NASDAQ
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
News Preview
Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).
Both the STOP-HS1 and STOP-HS2 studies m...
Themefolio
Profiler
Peergroup
© PR Newswire
08.03.2025
INCY
LISTED
NASDAQ
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
News Preview
Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg
Patients treated with baricitinib 4 mg saw significant regrowth of eyebrows and eyelashes at Week 36 compared to placebo
Positive data underscore Lilly's continued expansion across dermatologic conditions, wit...
Themefolio
Profiler
Peergroup
© BusinessWire
08.03.2025
INCY
LISTED
NASDAQ
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
News Preview
Incyte (Nasdaq:INCY) today announced results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (≥18 years) with prurigo nodularis (PN). The positive TRuE-PN1 data were presented...
Themefolio
Profiler
Peergroup
© BusinessWire
07.03.2025
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 13,351 shares of the Company’s common stock to 16 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of March 3, 2025, and were approved by...
Themefolio
Profiler
Peergroup
© BusinessWire
28.02.2025
INCY
LISTED
NASDAQ
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
News Preview
Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando.
"We look forward to sharing new data for ruxolitinib cream (Opzelura®) across multiple indications, including...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
INCY
LISTED
NASDAQ
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
News Preview
Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines, with an initial focus on collaboration targets selected by Incyte.
This press release features multimedia. View the full release her...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conferences
News Preview
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March:
Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 11:10 am (EST)
Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 9:20 am (EST)
The presentations will be webcast live...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
INCY
LISTED
NASDAQ
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
News Preview
Incyte (Nasdaq:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided full year 2025 financial guidance.
"2024 was an important year for Incyte, with a 15% increase in total revenues, driven by strong growth from both Jakafi and Opzelura, as well as significant progress across our R&...
Themefolio
Profiler
Peergroup
© BusinessWire
07.02.2025
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 16,301 shares of the Company’s common stock to 24 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of February 3, 2025, and were approved...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
INCY
LISTED
NASDAQ
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
News Preview
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 8:00 a.m. ET on Monday, February 10, 2025.
The schedule for the press release and conference call/webcast is as follows:
• Q4 & YE 2024 Press Release:
February 10, 2025 at 7:00 a.m. ET...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
INCY
LISTED
NASDAQ
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Incyte (Nasdaq:INCY) will provide an update on commercial growth, clinical progress and significant 2025 catalysts during a presentation today at 10:30 a.m. PT at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
“With significant advancements being made across our portfolio, 2025 will be a transformational year not only for In...
Themefolio
Profiler
Peergroup
© BusinessWire
09.01.2025
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 9,502 shares of the Company’s common stock to 14 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of January 2, 2025, and were approved by...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
